XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 110.7 $ 258.4
Marketable investment securities 82.5 81.4
Trade accounts receivable 102.2 91.3
Inventory 19.6 15.3
Prepaid taxes 17.8 18.4
Prepaid expenses and other current assets 19.5 20.0
Total current assets 352.3 484.8
Operating lease right-of-use assets 110.6 81.8
Long-term marketable investment securities 66.0 59.0
Property, plant, and equipment, net 67.5 43.5
Intangibles, net 370.8 404.1
Goodwill 236.5 239.2
Other assets 8.3 8.3
Total assets 1,212.0 1,320.7
Current liabilities:    
Accounts payable 29.6 29.6
Accrued liabilities 85.3 156.5
Current maturities of operating lease liabilities 14.0 13.0
Deferred revenues 0.2 5.2
Total current liabilities 129.1 204.3
Unrecognized tax benefits 27.9 27.9
Long-term deferred taxes 10.5 35.8
Noncurrent operating lease liabilities 123.3 79.3
Other long-term liabilities 4.6 5.6
Total liabilities 295.4 352.9
Commitments and contingencies
Stockholders’ equity:    
Common stock, 80.9 million and 80.0 million shares outstanding at September 30, 2022 and December 31, 2021, respectively 0.8 0.8
Additional paid-in capital 1,251.0 1,226.3
Accumulated other comprehensive loss (11.3) (5.1)
Accumulated deficit (323.9) (254.2)
Total Myriad Genetics, Inc. stockholders’ equity 916.6 967.8
Non-controlling interest 0.0 0.0
Total stockholders' equity 916.6 967.8
Total liabilities and stockholders’ equity $ 1,212.0 $ 1,320.7